Legal and Regulatory Status as of 2026 BPC 157 is not approved by the FDA, EMA, or any major regulatory agency for any therapeutic use
Additionally, CYP51A1 interacts with 15 core enzymes in the cholesterol biosynthesis pathway, including HMG-CoA reductase (HMGCR), FDFT1, dehydrocholesterol reductases (DHCRs), sigma non-opioid intracellular receptor 1 (SIGMAR1), and squalene epoxidase (SQLE), further supporting its central role in maintaining lipid homeostasis [47]
Body Protection Compound-157, more commonly known asBPC-157, is an artificial peptide made from a fragment of a protein isolated in human gastric juice
The substantia nigras (compacta and reticulata) structure (given serotonin synthesis significantly increased following both acute and chronic treatments) occurred as a particular point of pentadecapeptide BPC 157 [67]